Compare Kinross Gold Corporation (KGC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Sana Biotechnology Inc — how do they compare? Kinross Gold Corporation trades at $23.07 (market cap $26.63B), while Sana Biotechnology Inc trades at $3.23 (market cap $873.84M). The key difference: Kinross Gold Corporation is far larger — about 30.5× Sana Biotechnology Inc's market cap, and Kinross Gold Corporation pays a 0.64% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KGC | SANA | |
|---|---|---|
Market Cap | $26.63B | $873.84M |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $5.92 |
52-Week Low | $15.42 | $2.68 |
Enterprise Value | $25.18B | $848.03M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $22.65, up 0.35% with strong fundamentals including 35.99% net margin and 35.15% ROE. The stock shows bearish technical signals despite consistent earnings beats and analyst consensus of $37.20 price target. Recent cash flow growth from $259M in 2024 to $1.13B in 2025 supports dividend payments and exploration projects.
KGC presents value opportunity with P/E of 9.6x below industry averages, though technical weakness and gold price volatility pose risks. Production growth to 2.3M+ ounces by 2028 and net cash position provide upside catalysts if gold prices stabilize.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
